Researchers have identified a gene¹ that drives the development of tumours³ in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development. The team discovered that, when CUX1 is deactivated⁴, a biological pathway is activated⁵ that increases tumour² growth. Drugs that inhibit⁶ the biological pathway are currently being used in the clinic and are in development thus highlighting a potential new targeted therapy for patients with this type of cancer-causing mutation⁷.

 

Around 300,000 people in the UK each year are diagnosed with cancer, and for more than 3,000 of these patients, an inactive CUX1 gene may be an underlying⁸ factor for their disease.

 

"Our research is a prime example of how understanding the genetic⁹ code of cancers can drive the search for targeted cancer therapies that work more effectively and efficiently¹⁰, says Dr David Adams, lead author from the Wellcome Trust Sanger Institute. "This could improve the lives of thousands of people suffering from cancer."

 

The team used genetic data from over 7,600 cancer patients, collected and sequenced by the International Cancer Genome Constortium (ICGC) and other groups. They found that in around one per cent of the cancer genomes studied, mutations deactivated CUX1, an event associated with tumour growth.

 

CUX1 is mutated at a relatively¹¹ low frequency, but across many different types of cancer. Because previous studies focused on genes¹² that are mutated at a high rate in one cancer type to find cancer drivers, CUX1 was missed as a driver of cancer.

 

"Our work harnesses the power of combining large-scale cancer genomics with experimental genetics," says Dr Chi Wong, first author from the Wellcome Trust Sanger Institute and practising Haematologist at Addenbrooke's Hospital. "CUX1 defects are particularly common in myeloid blood cancers, either through mutation or acquired loss of chromosome¹³ 7q. As these patients have a dismal¹⁴（凄凉的） prognosis currently, novel targeted therapies are urgently needed."

 

"Data collected from large consortia such the ICGC, provides us with a new and broader way to identify genes that can underlie¹⁵ the development of cancers," says Professor David Tuveson from Cold Spring Harbor Laboratory. "We can now look at cancers as groups of diseases according to their tissues of origin and collectively examine and compare their genomes.

 

The team silenced CUX1 in cultured cells to understand how inactivating¹⁶ it might lead to the development of tumours. They found that when CUX1 is deactivated, it had a knock-on effect on a biological inhibitor, PIK3IP1, reducing its inhibitory effects. This mobilises an enzyme¹⁷ responsible for cell growth, phosphoinositide 3-kinase (PI3K), increasing the rate of tumour progression.

 

The team has already identified several dozen other genes that when mutated at a low frequency could promote cancer development. They plan to silence these genes in mice to fully¹⁸ understand how their inactivation¹⁹ may lead to cancer development and the mechanisms²⁰ by which this occurs.

 

"Drugs that inhibit PI3K signalling are currently undergoing clinical trial," says Professor Paul Workman, Deputy Chief Executive and Head of Cancer Therapeutics at The Institute of Cancer Research, London. "This discovery will help us to target these drugs to a new group of patients who will benefit from them and could have a dramatic effect on the lives of many cancer sufferers."

点击收听单词发音